AstraZeneca, now the most valuable London-listed company, has received international attention thanks to its hot pursuit of a coronavirus vaccine.
It sealed U.S. government funding last month and aims to produce a billion doses this and next year.
But while the recent buzz around the British firm has focused on a vaccine, cancer and heart medications are still its core business.
On Monday (June 1) AstraZeneca clinched expanded regulatory backing for two medications, including one for major cancer treatment Lynparza.
A panel of the European health regulator gave it the go ahead for use on a form of advanced pancreatic cancer.
Also on Monday, the company got a green light from the U.S. for a heart medication.
Meanwhile, AstraZeneca's covid vaccine manufacturing partner Oxford Biomedica last week signed a one-year deal with with the drugs firm.
The vaccine has been developed by researchers at the University of Oxford and licensed to AstraZeneca.
It's currently being tested on humans.
The drugmaker is in talks with governments and global partners over its efforts to boost production.
AstraZeneca shares were up 1% in afternoon trade.
